Latest Transmembrane Prolyl 4 Hydroxylase Pipeline Review, H2 2016, provides in depth analysis on Cellular Tumor Antigen P53 (Tumor Suppressor P53 or Antigen NY-CO-13) targeted pipeline therapeutics.
Transmembrane Prolyl 4 Hydroxylase therapeutics industry report provides comprehensive information on the therapeutics under development for Transmembrane Prolyl 4 Hydroxylase, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Transmembrane Prolyl 4 Hydroxylase and features dormant and discontinued projects.
Browse more detail information about Transmembrane Prolyl 4 Hydroxylase market report at: http://www.absolutereports.com/transmembrane-prolyl-4-hydroxylase-hypoxia-inducible-factor-prolyl-hydroxylase-4-or-p4htm-or-ec-1-14-11-pipeline-review-h2-2016-10393275
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Key players in Transmembrane Prolyl 4 Hydroxylase – Pipeline Review, H2 2016:
- Akebia Therapeutics, Inc.
- Bayer AG
- Daiichi Sankyo Company, Limited
- FibroGen, Inc.
- GlaxoSmithKline Plc
- Japan Tobacco Inc.
- Merck & Co., Inc.
- Sigmoid Pharma Limited
Get a PDF Sample of Transmembrane Prolyl 4 Hydroxylase Market Research Report at: http://www.absolutereports.com/enquiry/request-sample/10393275
Drug Profiles of Included in Transmembrane Prolyl 4 Hydroxylase Therapeutics Development Market Report
And other drug profiles
Have any query? ask our expert @ http://www.absolutereports.com/enquiry/pre-order-enquiry/10393275
Key Topics Covered:
2.Transmembrane Prolyl 4 Hydroxylase Overview
3.Transmembrane Prolyl 4 Hydroxylase Therapeutics Development
4.Pipeline Products for Transmembrane Prolyl 4 Hydroxylase – Overview
5.Pipeline Products for Transmembrane Prolyl 4 Hydroxylase – Comparative Analysis
6.Transmembrane Prolyl 4 Hydroxylase – Therapeutics under Development by Companies
7.Transmembrane Prolyl 4 Hydroxylase – Therapeutics under Investigation by Universities/Institutes
8.Transmembrane Prolyl 4 Hydroxylase Products Glance
9.Late Stage Products
10.Clinical Stage Products
11.Early Stage Products
12.Transmembrane Prolyl 4 Hydroxylase – Products under Development by Companies
13.Transmembrane Prolyl 4 Hydroxylase – Products under Investigation by Universities/Institutes
14.Transmembrane Prolyl 4 Hydroxylase – Companies Involved in Therapeutics Development
15.Transmembrane Prolyl 4 Hydroxylase Drug Profiles
16.Transmembrane Prolyl 4 Hydroxylase Dormant Projects
17.Transmembrane Prolyl 4 Hydroxylase Discontinued Products
18.Transmembrane Prolyl 4 Hydroxylase Featured News & Press Releases
Sep 19, 2016: Akebia Announces Publication of Phase 2b Data for Vadadustat in Non-Dialysis Patients with Anemia Related to Chronic Kidney Disease
Aug 22, 2016: Akebia Announces Publication Highlighting Need for New Solutions in Treating Dialysis Patients
Aug 08, 2016: Akebia Initiates INNO2VATE Phase 3 Program for Vadadustat in Dialysis Patients With Anemia Related to Chronic Kidney Disease
Jul 25, 2016: Astellas And Fibrogen Announce First Patient Treated In Phase 3 Studies And Positive Phase 2 Results Of Roxadustat In Patients With Chronic Kidney Disease In Japan
Jun 09, 2016: Fibrogen Announces Initiation By Astellas Of Phase 3 Clinical Study In Japan Of Roxadustat/ASP1517 For The Treatment Of Anemia Of Chronic Kidney Disease Triggering $10.0 Million Milestone Payment
May 23, 2016: Akebia Announces Positive Vadadustat Data Demonstrating No Clinically Significant Drug-Drug Interaction
Get Discount on Transmembrane Prolyl 4 Hydroxylase Market Research Report at: http://www.absolutereports.com/enquiry/request-discount/10393275
This 70 pages research study help to:
– Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
– Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
– Identify and understand important and diverse types of therapeutics under development for Transmembrane Prolyl 4 Hydroxylase
– Identify potential new clients or partners in the target demographic
– Develop strategic initiatives by understanding the focus areas of leading companies
– Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
– Devise corrective measures for pipeline projects by understanding Transmembrane Prolyl 4 Hydroxylase pipeline depth and focus of Indication therapeutics
– Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
– Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
About Absolute Report:
Absolute Reports is an upscale platform to help key personnel in the business world in strategizing and taking visionary decisions based on facts and figures derived from in depth market research. We are one of the top report resellers in the market, dedicated towards bringing you an ingenious concoction of data parameters.
Mr. Ameya Pingaley
+1-408 520 9750
Email – firstname.lastname@example.org